The Technical Analyst
Biostage, Inc. [BSTG]
Exchange: PNK Industry: Biotechnology
Biostage, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.75% $4.03
America/New_York / 19 jul 2023 @ 15:14
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 57.82 mill |
| EPS: | -0.650 |
| P/E: | -6.20 |
| Earnings Date: | Aug 01, 2023 |
| SharesOutstanding: | 14.35 mill |
| Avg Daily Volume: | 0.0010 mill |
| RATING 2023-08-15 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.20 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -6.20 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 3.82 - 4.08 ( +/- 3.29%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-11 | He Junli | Buy | 220 640 | Stock Option (right to buy) |
| 2023-12-27 | He Junli | Buy | 2 700 | Common Stock |
| 2023-12-14 | He Junli | Buy | 900 | Common Stock |
| 2023-12-06 | He Junli | Buy | 1 500 | Common Stock |
| 2023-09-11 | He Junli | Buy | 1 500 | Common Stock |
| INSIDER POWER |
|---|
| 78.40 |
| Last 94 transactions |
| Buy: 5 930 750 | Sell: 1 021 989 |
Forecast:
01:40 - $3.90
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.03 (0.75% ) |
| Volume | 0.0045 mill |
| Avg. Vol. | 0.0010 mill |
| % of Avg. Vol | 466.36 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BSTG
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BSTG
Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company is engaged in developing Biostage Esophageal Implant for the treating esophageal cancer. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.
Latest Press Releases
2023-07-18 09:00:00 - Press Release
Biostage Activated Mayo Clinic As The First Site For Clinical Trial In Severe Esophageal Disease
Holliston, mass. , july 18, 2023 /prnewswire/ -- biostage, inc. (otcqb: bstg) ("biostage" or the "company"), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, including cancer, trauma and birth defects initially in the esophagus and the airway, today announced that it officially activated the site with mayo clinic for its clinical trial as to severe esophageal disease, being its first clinical trial in the united states.
2022-12-28 08:30:00 - Press Release
Biostage Selects Iqvia To Manage Its Fda-approved Clinical Trial In Severe Esophageal Disease, Including Cancer
Iqvia was selected because of its dedicated gastrointestinal team and depth of experience in running cell-therapy clinical trials. holliston, mass.
2022-08-04 08:00:00 - Press Release
Biostage Schedules Conference Call And Webcast For Q2 2022 Results
Holliston, mass. , aug. 4, 2022 /prnewswire/ -- biostage, inc. (otcqb: bstg) ("biostage" or the "company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the mayo clinic and published last august) and fda approval to commence a clinical trial of the biostage esophageal implant for severe esophageal disease including cancer, today announced that it will release q2 2022 financial results on august 4, 2022 and host a conference call and webcast on august 5, 2022 at 9:00 am et to discuss financial results and business updates for the second-quarter 2022.
2022-03-30 14:49:00 - Press Release
Biostage Announces Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2021 Financial Results
Holliston, mass. , march 30, 2022 /prnewswire/ -- biostage, inc. (otcqb: bstg) ("biostage" or the "company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the mayo clinic and published last august) and fda approval to commence a clinical trial of the biostage esophageal implant for severe esophageal disease including cancer, today announced that it will be hosting a conference call to discuss fourth quarter and full year financial results.
2021-08-13 16:05:00 - Press Release
Biostage Reports Q2 2021 Financial Results
Holliston, mass., aug. 13, 2021 /prnewswire/ -- biostage, inc. (otcqb: bstg) ("biostage" or the "company"), a bioengineering company developing next-generation esophageal implants based its novel cellframe™ and cellspan™ technology, today announced its financial results for the three and six months ended june 30, 2021.
Latest News
2022-11-15 14:38:04 - Seeking Alpha
Biostage, Inc. (BSTG) Q3 2022 Earnings Call Transcript
Biostage, Inc. (OTC:BSTG) Q3 2022 Earnings Conference Call November 15, 2022 9:00 AM ET Company Participants David Green - Interim Chief Executive Officer Joe Damasio - Chief Financial Officer Conference Call Participants Operator Greetings. Welcome to the Biostage Q3 2022 Conference Call.
2022-08-04 08:00:00 - PRNewsWire
Biostage Schedules Conference Call and Webcast for Q2 2022 Results
HOLLISTON, Mass. , Aug. 4, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including cancer, today announced that it will release Q2 2022 financial results on August 4, 2022 and host a conference call and webcast on August 5, 2022 at 9:00 AM ET to discuss financial results and business updates for the second-quarter 2022.
2022-06-24 13:16:31 - Seeking Alpha
Biostage Begins U.S. Uplisting IPO Rollout
Biostage has filed to raise capital via an uplisting IPO to Nasdaq. The firm is developing treatments for the various gastrointestinal system and airway conditions.
2022-05-17 10:43:12 - Seeking Alpha
Biostage, Inc. (BSTG) Interim CEO David Green on Q1 2022 Results - Earnings Call Transcript
Biostage, Inc. (OTC:BSTG) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET Company Participants Peter Pellegrino - Interim Vice President of Finance David Green - Interim Chief Executive Officer Operator Greetings. Welcome to the Biostage Q1 2022 Conference Call.
2022-03-30 14:49:00 - PRNewsWire
Biostage Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2021 Financial Results
HOLLISTON, Mass. , March 30, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including cancer, today announced that it will be hosting a conference call to discuss fourth quarter and full year financial results.
2021-08-13 16:05:00 - PRNewsWire
Biostage Reports Q2 2021 Financial Results
HOLLISTON, Mass., Aug. 13, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants based its novel Cellframe™ and Cellspan™ technology, today announced its financial results for the three and six months ended June 30, 2021.
2021-05-24 16:05:00 - PRNewsWire
Biostage Reports Q1 2021 Financial Results
HOLLISTON, Mass., May 24, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants based its novel Cellframe™ and Cellspan™ technology, today announced its financial results for the three months ended March 31, 2021.